Cogent Biosciences (COGT)
(Delayed Data from NSDQ)
$11.11 USD
+0.56 (5.31%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $11.10 -0.01 (-0.09%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Income Statements
Fiscal Year end for Cogent Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 8 | 23 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 8 | 23 |
Selling & Adminstrative & Depr. & Amort Expenses | 208 | 148 | 76 | 90 | 55 |
Income After Depreciation & Amortization | -208 | -148 | -76 | -82 | -32 |
Non-Operating Income | 16 | 8 | 3 | 7 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -192 | -140 | -72 | -75 | -32 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -192 | -140 | -72 | -75 | -32 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -192 | -140 | -72 | -75 | -32 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -211 | -149 | -75 | -81 | -31 |
Depreciation & Amortization (Cash Flow) | -3 | -1 | 0 | 1 | 1 |
Income After Depreciation & Amortization | -208 | -148 | -76 | -82 | -32 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 79.66 | 58.74 | 38.73 | 11.08 | 7.62 |
Diluted EPS Before Non-Recurring Items | -2.42 | -2.39 | -1.87 | -16.08 | -4.16 |
Diluted Net EPS (GAAP) | -2.42 | -2.39 | -1.87 | -16.17 | -4.16 |
Fiscal Year end for Cogent Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 64.38 | 62.41 | 58.23 | 59.58 | 47.08 |
Income After SG&A, R&D, and Dept/Amort Expenses | -64.38 | -62.41 | -58.23 | -59.58 | -47.08 |
Non-Operating Income | 5.44 | 4.06 | 3.86 | 4.20 | 3.01 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -58.95 | -58.35 | -54.36 | -55.38 | -44.08 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -58.95 | -58.35 | -54.36 | -55.38 | -44.08 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -58.95 | -58.35 | -54.36 | -55.38 | -44.08 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | 99.24 | 94.81 | 86.73 | 86.17 | 74.75 |
Diluted EPS Before Non-Recurring Items | -0.59 | -0.62 | -0.63 | -0.64 | -0.59 |
Diluted Net EPS (GAAP) | -0.59 | -0.62 | -0.64 | -0.64 | -0.59 |